Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Readability, content, quality and accuracy assessment of internet-based patient education materials relating to labor analgesia.

Murphy J, Vaughn J, Gelber K, Geller A, Zakowski M.

Int J Obstet Anesth. 2019 Aug;39:82-87. doi: 10.1016/j.ijoa.2019.01.003. Epub 2019 Jan 8.

PMID:
31000314
2.

Cytological features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Zhang Z, Chhieng D, Harshan M, Zheng X, Zakowski M.

J Am Soc Cytopathol. 2019 Jan - Feb;8(1):5-10. doi: 10.1016/j.jasc.2018.07.007. Epub 2018 Aug 8.

PMID:
30929759
3.

Obstetric Anesthesiology in the United States: Current and Future Demand for Fellowship-Trained Subspecialists.

Gelber K, Kahwajian H, Geller AW, Zakowski MI.

Anesth Analg. 2018 Dec;127(6):1445-1447. doi: 10.1213/ANE.0000000000003809. No abstract available.

PMID:
30252705
4.

Old Ways Do Not Open New Doors: Norepinephrine for First-Line Treatment of Spinal Hypotension.

Vallejo MC, Zakowski MI.

Anesth Analg. 2018 Jun;126(6):1809-1811. doi: 10.1213/ANE.0000000000002491. No abstract available.

PMID:
29762220
5.

Analytic inquiry: Molecular testing in lung cancer.

Zakowski MF.

Cancer Cytopathol. 2017 Jun;125(S6):470-476. doi: 10.1002/cncy.21866. Review.

6.

Accuracy of Blood Loss Measurement during Cesarean Delivery.

Doctorvaladan SV, Jelks AT, Hsieh EW, Thurer RL, Zakowski MI, Lagrew DC.

AJP Rep. 2017 Apr;7(2):e93-e100. doi: 10.1055/s-0037-1601382.

7.

Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.

Pan A, Zakowski M.

Clin Obstet Gynecol. 2017 Jun;60(2):447-458. doi: 10.1097/GRF.0000000000000288. Review.

PMID:
28426507
8.

Zika virus: review and obstetric anesthetic clinical considerations.

Padilla C, Pan A, Geller A, Zakowski MI.

J Clin Anesth. 2016 Dec;35:136-144. doi: 10.1016/j.jclinane.2016.07.034. Epub 2016 Aug 11. Review.

PMID:
27871511
9.

"…That which we call a rose…": A critical analysis of rapid on-site evaluation.

Zakowski MF.

Cancer Cytopathol. 2016 Dec;124(12):857-861. doi: 10.1002/cncy.21784. Epub 2016 Nov 11. No abstract available.

10.

Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

Zakowski MF, Rekhtman N, Auger M, Booth CN, Crothers B, Ghofrani M, Khalbuss W, Laucirica R, Moriarty AT, Tabatabai ZL, Barkan GA.

Arch Pathol Lab Med. 2016 Oct;140(10):1116-20. doi: 10.5858/arpa.2015-0316-OA. Epub 2016 Aug 23.

11.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

12.

Opportunities for improvement in care among women with severe maternal morbidity.

Ozimek JA, Eddins RM, Greene N, Karagyozyan D, Pak S, Wong M, Zakowski M, Kilpatrick SJ.

Am J Obstet Gynecol. 2016 Oct;215(4):509.e1-6. doi: 10.1016/j.ajog.2016.05.022. Epub 2016 May 19.

PMID:
27210068
13.

Guidelines and consensus: statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Sharma K, Afshar YR, Bairey-Merz CN, Tapson V, Zakowski M, Kilpatrick SJ.

Pulm Circ. 2016 Mar;6(1):143. doi: 10.1086/685113. No abstract available.

14.

SOAP Delivers: Options for Labor Pain.

Vallejo MC, Zakowski MI, Scavone BM.

Anesth Analg. 2016 Apr;122(4):1223. doi: 10.1213/ANE.0000000000001138. No abstract available.

PMID:
26991627
15.

Standardized terminology and nomenclature for respiratory cytology: The Papanicolaou Society of Cytopathology guidelines.

Layfield LJ, Baloch Z, Elsheikh T, Litzky L, Rekhtman N, Travis WD, Zakowski M, Zarka M, Geisinger K.

Diagn Cytopathol. 2016 May;44(5):399-409. doi: 10.1002/dc.23457. Epub 2016 Mar 15. Erratum in: Diagn Cytopathol. 2016 Aug;44(8):714. Rektman, Natasha [corrected to Rekhtman, Natasha].

PMID:
26990836
16.

Cytology nomenclature and 2015 World Health Organization classification of lung cancer.

Zakowski MF.

Cancer Cytopathol. 2016 Feb;124(2):81-8. doi: 10.1002/cncy.21628. Epub 2015 Oct 13. Review. No abstract available.

17.

Imaging appearances of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.

Foran PJ, Hayes SA, Blair DJ, Zakowski MF, Ginsberg MS.

Clin Imaging. 2015 Mar-Apr;39(2):243-6. doi: 10.1016/j.clinimag.2014.10.017. Epub 2014 Oct 30.

PMID:
25496668
18.

Low interobserver agreement in cytology grading of mucinous pancreatic neoplasms.

Sigel CS, Edelweiss M, Tong LC, Magda J, Oen H, Sigel KM, Zakowski MF.

Cancer Cytopathol. 2015 Jan;123(1):40-50. doi: 10.1002/cncy.21492. Epub 2014 Oct 29.

19.

Obstetric-related neurological complications.

Zakowski MI.

Int Anesthesiol Clin. 2014 Summer;52(3):40-60. doi: 10.1097/AIA.0000000000000025. No abstract available.

PMID:
24946042
20.

Small-cell lung cancers in patients who never smoked cigarettes.

Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, Berger MF, Pietanza MC.

J Thorac Oncol. 2014 Jun;9(6):892-6. doi: 10.1097/JTO.0000000000000142.

21.

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.

Kapur S, Xiao H, Zakowski MF, Hameed MR, Levin MB.

World J Oncol. 2014 Apr;5(2):81-89. doi: 10.14740/wjon779w. Epub 2014 May 6.

22.

[Policies and reporting guidelines for small biopsy specimens of mediastinal masses].

Marchevsky A, Marx A, Strobel P, Suster S, Venuta F, Marino M, Yousem S, Zakowski M; International Thymic Malignancy Interest Group.

Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):104-9. doi: 10.3779/j.issn.1009-3419.2014.02.07. Review. Chinese. No abstract available.

23.

Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage.

Ridge CA, Huang J, Cardoza S, Zabor EC, Moskowitz CS, Zakowski MF, Ginsberg MS.

AJR Am J Roentgenol. 2013 Nov;201(5):959-63. doi: 10.2214/AJR.12.10033. Erratum in: AJR Am J Roentgenol. 2014 Jan;202(1):248.

PMID:
24147464
24.

The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.

Paintal A, Raparia K, Zakowski MF, Nayar R.

Cancer Cytopathol. 2013 Dec;121(12):703-7. doi: 10.1002/cncy.21342. Epub 2013 Sep 4.

25.

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers.

Chaft JE, Rekhtman N, Sima CS, Rusch V, Kris MG, Zakowski M, Azzoli CG.

Cancer Chemother Pharmacol. 2013 Oct;72(4):931-4. doi: 10.1007/s00280-013-2263-1. Epub 2013 Aug 22.

26.

Lung cancer in the era of targeted therapy: a cytologist's perspective.

Zakowski MF.

Arch Pathol Lab Med. 2013 Dec;137(12):1816-21. doi: 10.5858/arpa.2013-0029-RA. Epub 2013 Apr 18. Review.

PMID:
23597048
27.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N.

Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.

28.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ.

Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.

29.

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.

Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.

30.

Lung carcinoma in the era of personalized medicine: the role of cytology.

Zakowski MF, Bibbo M.

Acta Cytol. 2012;56(6):587-9. doi: 10.1159/000345183. Epub 2012 Nov 24. No abstract available.

PMID:
23207435
31.

Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.

Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, Moreira AL, Zakowski MF, Travis WD, Sima CS, Kris MG, Ladanyi M.

Mod Pathol. 2013 Apr;26(4):511-22. doi: 10.1038/modpathol.2012.195. Epub 2012 Nov 30. Erratum in: Mod Pathol. 2014 Jan;27(1):163.

32.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2.

33.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

34.

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M.

Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26.

35.

Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study.

Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu H, Yatabe Y, Zakowski M, Witte B, Kuik DJ.

Mod Pathol. 2012 Dec;25(12):1574-83. doi: 10.1038/modpathol.2012.106. Epub 2012 Jul 20.

36.

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi: 10.1158/1078-0432.CCR-12-0912. Epub 2012 Jul 3.

37.

Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.

Hasanovic A, Ang D, Moreira AL, Zakowski MF.

Lung Cancer. 2012 Aug;77(2):299-305. doi: 10.1016/j.lungcan.2012.04.004. Epub 2012 Apr 26.

PMID:
22542171
38.

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Feb 15;18(4):1167-76. doi: 10.1158/1078-0432.CCR-11-2109. Epub 2012 Jan 6.

39.

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG.

Mol Cancer Ther. 2012 Feb;11(2):485-91. doi: 10.1158/1535-7163.MCT-11-0692. Epub 2011 Dec 1.

40.

Policies and reporting guidelines for small biopsy specimens of mediastinal masses.

Marchevsky A, Marx A, Ströbel P, Suster S, Venuta F, Marino M, Yousem S, Zakowski M.

J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1724-9. doi: 10.1097/JTO.0b013e31821ea57c. No abstract available.

41.

Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas.

Lampen-Sachar K, Zhao B, Zheng J, Moskowitz CS, Schwartz LH, Zakowski MF, Rizvi NA, Kris MG, Ginsberg MS.

Lung Cancer. 2012 Mar;75(3):332-5. doi: 10.1016/j.lungcan.2011.08.001. Epub 2011 Sep 3.

42.

Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.

Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, Riely GJ, Rekhtman N.

J Thorac Oncol. 2011 Nov;6(11):1849-56. doi: 10.1097/JTO.0b013e318227142d.

43.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W.

Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20.

44.

Role of cytology in the management of non-small-cell lung cancer.

Fischer AH, Cibas ES, Howell LP, Kurian EM, Laucirica R, Moriarty AT, Renshaw AA, Zakowski MF, Young NA.

J Clin Oncol. 2011 Aug 20;29(24):3331-2; author reply 3332-3. doi: 10.1200/JCO.2011.35.2534. Epub 2011 Jul 18. No abstract available.

PMID:
21768461
45.

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M.

Nat Genet. 2011 Jun 5;43(7):668-72. doi: 10.1038/ng.855.

46.

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.

Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG.

Clin Cancer Res. 2011 May 15;17(10):3500-6. doi: 10.1158/1078-0432.CCR-10-2102. Epub 2011 May 10.

47.

Novel handheld PET probes provide intraoperative localization of PET-avid lymph nodes.

González SJ, Wong J, González L, Brader P, Zakowski M, Gönen M, Fong Y, Strong VE.

Surg Endosc. 2011 Oct;25(10):3214-21. doi: 10.1007/s00464-011-1696-z. Epub 2011 Apr 22.

48.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Clin Oncol. 2011 May 20;29(15):2066-70. doi: 10.1200/JCO.2010.32.6181. Epub 2011 Apr 11.

49.

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, Zakowski MF, Moreira AL.

J Thorac Oncol. 2011 Mar;6(3):451-8. doi: 10.1097/JTO.0b013e31820517a3.

50.

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M.

Clin Cancer Res. 2011 Mar 1;17(5):1169-80. doi: 10.1158/1078-0432.CCR-10-2277. Epub 2011 Jan 19.

Supplemental Content

Loading ...
Support Center